Perindopril

Atkinson, Jeffrey

doi:10.1111/j.1527-3466.1992.tb00262.x

Cited by 3 publications

(3 citation statements)

References 116 publications

(83 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vitro release studies of patches were carried out in triplicate. After 6 h the release was found to be 94.24±0.94, 89.63±1.16, 88.42±1.85 and 80.38±1.04% for the formulations F 1, F 2, F 3 and F 4 respectively figure (5) and the data was analyzed by one way ANOVA and significant difference was observed between the means. In vitro release studies clearly showed that the percent release of perindopril was maximum i.e., 94.24% for formulation F 1.…”

Section: In Vitro Release Studiesmentioning

confidence: 96%

“…Perindopril Eribumine is an orally active, angiotensin converting enzyme inhibitor. The terminal half-life of perindopril is about 0.8 to 1 hr (5) . Following oral administration, perindopril is well absorbed and undergoes substantial first-pass metabolism by cytochrome P450 enzymes; the systemic bioavailability of perindopril is about 20%.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Design and Development of Buccal Mucoadhesive Drug Delivery System for Perindopril = تصميم و تطوير نظام إيتاء دواء فموي لدواء بيريندوبريل

Penjuri¹,

Saritha²,

Nagaraju³

2015

JJPS

View full text Add to dashboard Cite

The main objective of present study was to develop a buccal mucoadhesive drug delivery system for perindopril. Perindopril buccal mucoadhesive patches were developed by solvent casting technique using hydroxy propyl methylcellulose (HPMC), polycarbophil, sodium carboxymethylcellulose (SCMC) and sodium alginate as polymers for extended release of perindopril. Glycerine and DMSO were used as plasticizer and penetration enhancer respectively. Ethanol, methanol and dichloromethane were used as solvents. FTIR and DSC studies revealed no interaction between drug and polymers. The drug content in the perindopril patches was found to be uniform. The films exhibited good physical and mechanical properties. The surface pH of all the patches was within salivary pH range. Residual solvent content in patches are below the tolerated limits. The patches were found to have an extended release of the drug upto a period of 12 hours during ex vivo permeation studies with non-Fickian diffusion mechanism. The present study demonstrated the possibility of designing a buccal drug delivery system for perindopril.

show abstract

Section: In Vitro Release Studiesmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

Design and Development of Buccal Mucoadhesive Drug Delivery System for Perindopril = تصميم و تطوير نظام إيتاء دواء فموي لدواء بيريندوبريل

Penjuri¹,

Saritha²,

Nagaraju³

2015

JJPS

View full text Add to dashboard Cite

show abstract

“…However, a number of the studies included in this review had either small sample sizes or reflected open studies without proper placebo-controls. For example, the ACE-inhibitor perindopril has been studied extensively in Europe and North America, is well toler-ated 6,7 and demonstrates consistent antihypertensive efficacy over a 24-h dosing interval. 8,9 However, the data on its use in the elderly population is limited to open studies only.…”

Section: Introductionmentioning

confidence: 99%

Antihypertensive efficacy of the ACE-inhibitor perindopril in the elderly

Tanner

Cf³

2000

J Hum Hypertens

View full text Add to dashboard Cite

To assess the antihypertensive efficacy of the angiotensin-converting enzyme (ACE)-inhibitor, perindopril, in the elderly, patients Ͼ65 years of age with supine diastolic blood pressure (BP) у90 and р110 mm Hg at the end of a 4-week placebo washout period were treated with perindopril 4 -8 mg/daily vs placebo using a multicentre, randomised, double-blind, parallel group design. Of the 191 patients entered, 183 completed 8 weeks of double-blind therapy. Average age was 72-73 years. Supine and standing BP at the end of the placebo runin period were 173/96 vs 168/96 mm Hg. BPs were measured in the morning, 20-25 h after the previous day's dose (ie, at the end of the dosing interval). In the

show abstract

Low Dose Indapamide Plus Perindopril Combination Effects on Cardiovascular Structure and Function in Genetic Hypertension

Ibrahim

Schächter

Hughes

et al. 1999

Clin Exp Pharma Physio

View full text Add to dashboard Cite

1. Although the fixed combination preparations of thiazide and angiotensin-converting enzyme inhibitor are gaining wide acceptance in clinical practice, data on the basic pharmacology of the combinations are relatively limited. The long-term structural and functional effects of a fixed low dose (0.24 + 0.76 mg/kg per day) combination of indapamide + perindopril (I + P,S5590) is spontaneously hypertensive rats (SHR) were examined in the present study. 2. Male SHR (10-12 weeks) were treated with I + P or vehicle for 8 weeks. The blood pressure and heart rate were monitored by weekly measurements. At the end of the treatment period, left ventricular, aortic and intramyocardial coronary arteriole structures were assessed. Contractile and relaxant properties of mesenteric arteries were determined by wire-myography. 3. Indapamide + perindopril combination caused a significant lowering of both systolic (P < 0.001) and diastolic (P < 0.001) blood pressures. Left ventricle plus septum:bodyweight ratio (P < 0.001), aortic medial cross-sectional area (P < 0.05) and media:lumen ratios (P < 0.005) were all significantly reduced by I + P treatment. In contrast, the effect of I + P on intramyocardial coronary vascular structure did not reach statistical significance. There was some improvement in endothelium-independent vasorelaxation of mesenteric vessels but contractile responses to noradrenaline and calcium were unaffected by treatment. 4. In summary, a low dose I + P combination treatment of SHR partly normalizes both systolic and diastolic blood pressures. Cardiac and larger vessel hypertrophy was reversed but intramyocardial coronary arteriole structure was not as readily regressed by the end of the study.

show abstract

Perindopril

Cited by 3 publications

References 116 publications

Design and Development of Buccal Mucoadhesive Drug Delivery System for Perindopril = تصميم و تطوير نظام إيتاء دواء فموي لدواء بيريندوبريل

Design and Development of Buccal Mucoadhesive Drug Delivery System for Perindopril = تصميم و تطوير نظام إيتاء دواء فموي لدواء بيريندوبريل

Antihypertensive efficacy of the ACE-inhibitor perindopril in the elderly

Low Dose Indapamide Plus Perindopril Combination Effects on Cardiovascular Structure and Function in Genetic Hypertension

Contact Info

Product

Resources

About